Ami Asset Management Corp Biomarin Pharmaceutical Inc Transaction History

Ami Asset Management Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 24, 2024	SELL	$74.43 - $92.22 $526,964 - $652,917	-7,080 Reduced 2.05%	339,109 $27.9 Million
Q1 2024 Apr 19, 2024	BUY	$83.81 - $99.0 $9.91 Million - $11.7 Million	118,230 Added 51.86%	346,189 $30.2 Million
Q4 2023 Jan 19, 2024	SELL	$76.22 - $98.51 $6.61 Million - $8.54 Million	-86,669 Reduced 27.55%	227,959 $22 Million
Q3 2023 Oct 20, 2023	BUY	$85.07 - $94.48 $26.8 Million - $29.7 Million	314,628 New	314,628 $27.8 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Ami Asset Management Corp, based on Form 13F filings with the SEC.

Stay updated on Ami Asset Management Corp with notifications on news.